Market Overview

UPDATE: JP Morgan Maintains Integra LifeSciences at Neutral Following Model Update

Share:
Related IART
UPDATE: Integra LifeSciences Announces FDA Clearance And Controlled Market Release Of Expandable Interbody System For Spinal Surgery
Integra LifeSciences Introduces Integra Pocket Strip And Integra Shaped Strip DBM Implants

JP Morgan reiterated its Neutral rating and $43 price target on Integra LifeSciences (NASDAQ: IART).

JP Morgan commented, "For 2013, we continue to expect adjusted EPS of $3.14 (+1.3%) on total revenues of $878.1M (+5.5%). Excluding the impact of the medical device excise tax (~$0.29), earnings growth is projected at 10.7%. By division, we project Neuro growth of 4.0%, Orthopedics growth of 7.4%, and Instruments growth of (3.9%). Longer term, we see Integra as a 5-6% and 10-11% top- and bottom-line grower, respectively. This compares to management's long-term guidance ranges of 5-7% and 9-13%. For 2014, we model adjusted EPS of $3.48 (+11.2%) on total revenues of $925.6M (+5.4%)."

Integra LifeSciences closed at $38.78 on Wednesday.

Latest Ratings for IART

DateFirmActionFromTo
Mar 2015Piper JaffrayInitiates Coverage onOverweight
Feb 2015JefferiesMaintainsBuy
Aug 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (IART)

Around the Web, We're Loving...